1. Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s lymphoma. J Clin Oncol 2007; 25: 2000-2005.
2. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 2007; 357: 1916-1927.
3. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Eng J Med 2003; 348: 2386-2395.
4. Josting A, Reiser M, Rueffer U, et al. Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure? J Clin Oncol 2000; 18: 332-339.
5. Fermé C, Mounier N, Diviné M, et al. Intensive salvage chemotherapy with high-dose chemotherapy for patients with advanced HD in relapse or failure after initial chemotherapy: results of the GELA H89 trial. J Clin Oncol 2002; 20: 467-475.
6. Longo DL, Puffey PL, Zouny RC, et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.
7. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease, results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
8. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359; 2065-2071.
9. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and ASCT for patients with relapsing Hodgkinęs Disease: analysis of 280 patients from the French Registry. Bone Marrow Transplant 1997; 20: 21-26.
10. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2002; 20: 220-231.
11. Moskowitz CH, Nimer SD, Zelentz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
12. Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16: 116-123.
13. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol 2001; 113: 161-171.
14. Aparicio J, Segura A, Garcerá S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 1999; 10: 593-595.
15. Rodriguez J, Rodriguez MA, Farad L, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood 1999; 93: 3632-3636.
16. Bishton MJ, Lush RJ, Byrne JL, et al. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007; 136: 752-761.
17. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003; 14: 1762-1767.
18. Kuruvilla J, Nagy T, Pintilie M, et al. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006; 106: 353-360.
19. Bartlett N, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB59804. Ann Oncol 2007; 18: 1071-1079.
20. Santoro A, Magnagnoli M, Spina M, et al. Ifosfamide, gemcitabine and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007; 92: 35-41.
21. Rueffer JU, Ballova V, Glossmann J, et al. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - Results of the German Hodgkin Study Group. Leuk Lymphoma 2005; 46: 1561-1567.
22. Cavalieri E, Matturro A, Annechini G, et al. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 1803-1808.
23. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 211-216.
24. Jabbour E, Hosing C, Avers G, et al. Pretransplant positive positron emission tomography/gallium scan predict poor outcome in patients with recurrent/refractory Hodgkin’s lymphoma. Cancer 2007; 109: 2481-2489.
25. Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007; 109: 486-491.
26. Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23: 1522-1529.
27. Yahalom J, Gulati SC, Toia M, et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease. J Clin Oncol 1993; 11: 1062-1070.
28. Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008; 19: 1312-1319.
29. Gutierez-Delgado F, Holmberg L, Hooper H, et al. Autologous stem cell transplantation for Hodgkin’s disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32: 279-285.
30. Morschhauser F, Brice P, Fermé C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin’s lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26: 5980-5987.
31. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008: 326-333.
32. Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009; 146: 158-163.
33. Little R, Wittes RE, Longo DL, et al. Vinblastine for recurrent Hodgkin’s disease following autologous bone marrow transplant. J Clin Oncol 1998; 16: 584-588.
34. Venkatesh H, Di Bella N, Flynn TP, et al. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clin Lymphoma 2004; 5: 110-115.
35. Spencer A, Reed K, Artur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007; 37: 760-766.
36. Younes A. Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98: 310-314.
37. Oki Y, Pro B, Fayad LE, et al. A phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008; 112: 831-836.
38. Trelle S, Sezer O, Neumann R, et al. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin’s lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica 2007; 92: 568-569.
39. Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma 2008; 49: 883-889.
40. Kuruvilla J, Song K, Miller P, et al. A phase II study of thalidomide and vinblastine for paliative patients with Hodgkin’s lymphoma. Hematology 2006;11:25-29.
41. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 2004; 200: 1623-1633.
42. Smith SM, van Besien K, Carreras J, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008; 14: 904-912.
43. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996; 14: 572-578.
44. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667-678.
45. Milpied N, Fielding AK, Pearce R, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. J Clin Oncol 1996; 14: 1291-1296.
46. Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41: 765-770.
47. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455-462.
48. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257-264.
49. Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418-425.
50. Burroughs LM, O’Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 2008; 14: 1279-1287.
51. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365: 1906-1908.
52. Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009; 94: 230-238.
53. Carella AM, Cavaliere M, Lerma Em et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 2000; 18: 3918-3924.